Senate places Biosimilar Red Tape Elimination Act on legislative calendar
/ 1 min read
Table of Contents
Senator [Name - Note: The provided source does not list a sponsor, please check the specific bill record for the name] introduced this bill to change how biosimilars are handled by the FDA. A biosimilar is a drug that is highly similar to an already approved biological drug.
Why it matters: This is a regulatory change intended to lower the barrier for manufacturers to produce cheaper versions of biological drugs. Its impact depends entirely on whether the Senate decides to move it toward a vote and if it eventually passes both chambers and is signed by the President.
Who it affects
- Pharmaceutical companies that manufacture biosimilars
This information comes from Congress.gov regarding a Senate bill; please consult the official text at Congress.gov before relying on this information for legal or business decisions.
Agency: Senate
Source: Congress.gov — read the official document